Interest in Avacta’s Affimer technology continues to grow as biotech unveils latest research partnership
This time it is with OncoSec Medical, which wants to use its own gene delivery platform to deliver Avacta’s Affimers into tumour cells
Company
Avacta Group PLC
LON:AVCT
At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets. Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
207 stories · page 8 of 11
Avacta boss praises “strong” progress made in first half
“We have continued to grow the number and extent of the data packages demonstrating the power of the Affimer technology in therapeutic and non-therapeutic applications which build the commercial case and de-risk the technology for third par
Archive
Proactive news snapshot: Galantas Gold, Challenger Acquisitions, Kefi Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Avacta agrees licensing deal with antibody drug conjugates specialist Glythera
"I am delighted with the reciprocal arrangements that we have put in place with Glythera allowing both companies to develop Affimer-Permalink drug conjugates," said Avacta's CEO, Alastair Smith
Archive
Proactive news snapshot: MySQUAR, Corero Network Security, Bezant Resources, Fox Marble …
A glance at some of the day's highlights from the Proactive Investors newswire
Contract wins boost shares in both WANdisco and Corero Network Security
Some of the biggest risers and fallers in the London market on Wednesday
Investments and investor services
FTSE 100 closes higher; Next keeps festive cheer rolling
On a separate note, Mifid II comes into force today with the aim of increasing transparency and making everyone in the investment chain more accountable for their decisions
Archive
Proactive news snapshot: FFI Holdings, Metal Tiger, Bezant Resources, Kin Group
A look at some of the day's highlights from the Proactive Investors newswire
Savannah Resources soars as it receives environmental permits for high-grade copper deposits in Oman
Some of the main news-driven risers and fallers in London on Wednesday ...
Avacta partner to present data on breakthrough technology at Barcelona conference
Avacta’s chief executive, Dr Alastair Smith, said the presentation provided “strong, independent validation of the technical performance of Affimer reagents and is important to our commercialisation of the technology”
Investments and investor services
FTSE 100 joins global sell-off to close lower
Data out yesterday suggested Chinese industrial production growth is starting to slow, which is bad news for miners, but Fresnillo topped Footsie today
Archive
Proactive news snapshot: Tlou Energy, Goldplat, Rose Petroleum …
A glance at some of the day's highlights from the Proactive Investors newswire
Interest in Affimer technology at record levels, which bodes well for Avacta
Affimers are small, engineered proteins, some of which are of human origin and some plant-derived. They are capable of binding specific molecular targets, in a similar way to antibodies.
FTSE 100 closes near flat as traders look for direction; Dow Jones surges
The UK blue chip index closed its account on Tuesday up 2.09 at 7,526.
Archive
Proactive news snapshot: Strategic Minerals, MySQUAR, Haydale Graphene Industries …
A glance at some of the day's highlights from the Proactive Investors newswire
Conroy Gold rallies after being awarded all costs in court battle with dissident shareholder
A look at some of the top risers and fallers in London today
FTSE 100 closes higher as Catalan president's speech in the spotlight
The UK benchmark finished the day at 7,538, up 30.38 points
Archive
Proactive news snapshot: Rose Petroleum, Ortac Resources, SDX Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
SSE rallies despite HSBC trimming its price target
SSE may have rallied, but Centrica remained down in the dumps, after HSBC trimmed its price target for the British Gas owner to 190p from 202p.
Patient heal thyself - Avacta teams up with Finnish biotech firm to develop system that allows body to create its own drugs
Avacta chief executive, Dr Alastair Smith, said the collaboration could lead to “multiple therapeutic benefits and create a best-in-class gene therapy combination with significant potential”